These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2008-006369-10||Preliminary assessment of the clinical tolerability, safety and immunogenicity of three different doses of grass pollen-derived peptides for oral use in antigen-specific immunotherapy of seasonal alle...||bad-data|
|Not reported||2010-023176-12||Clinical efficacy, immunogenicity, clinical tolerability and assessment of safety of gpASIT+TM administered orally, according to two administration schedules, for the prophylaxis of seasonal grass pol...||2012-01-04||due-trials|
|Completed, but no date||2011-004486-33||Safety, clinical tolerability and immunogenicity of gpASIT+TM administered subcutaneously to hay fever patients either alone or in presence of DnaK immunoregulating adjuvant.||bad-data|
|Not reported||2013-000056-18||Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.||2013-12-09||due-trials|
|Completed, but no date||2013-005445-37||A prospective, randomized, double-blind placebo-controlled multi-centre dose-finding study of 3 different regimens of gpASIT+TM administered subcutaneously to adult patients with grass pollen-induced ...||bad-data|
|Not reported||2015-002105-11||A multicenter, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass po...||2016-09-15||due-trials|
|Not reported||2016-000557-13||Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients.||2017-01-23||due-trials|
|Ongoing||2017-002911-33||A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass poll...||not-yet-due|
|Ongoing||2017-004616-19||A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe grass pollen allergic rh...||not-yet-due|